Ketamine for resistant depression: a scoping review

Actas Esp Psiquiatr. 2022 May;50(3):144-159. Epub 2022 May 1.ABSTRACTKetamine is a fast-acting anesthetic with hypnotic properties. Moreover, could potentially improve affective symptoms in patients with refractory depressive disorder. Objective. explore the scientific literature available until December 10, 2021, about the efficacy and safety of ketamine in patients with treatment-refractory major depressive disorder. Material and methods. Scoping review that included PubMed and Scopus. Records of clinical trials and publications with empirical data in English and Spanish were included.PMID:35643973

Source: Actas Espanolas de Psiquiatria - June 1, 2022 Category: Psychiatry Authors: Tuta-Quintero Eduardo Acero Angela Le ón Mateo L ópez-Zuleta Melanie Prieto-Fern ández Valentina Charry David Collazos Estefania Rojas-Sanchez Natalia Vargas-Camacho Andr és Rodr íguez-Olarte Angel Guerrero Juan Pimentel Juan Source Type: research